Scinai Immunotherapeutics Ltd - ADR
SCNI
Get informed when a big investor buys or sells
+ FollowMarket Cap$422.89K
Close$
$1.67
482.6% upside
Current Fair Value
482.6% upsideUndervalued by 482.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $422,890.00 |
|---|---|
| Enterprise Value | $804,895.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.6 |
| Beta | 2.05 |
| Outstanding Shares | 946 |
Return
| Return on Equity | -27.13% |
|---|---|
| Return on Assets | -18.14% |
| Return on Invested Capital | -61.83% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 0.57 |
| Enterprise Value to EBIT | -0.09 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 4.34 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 10, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Scinai Immunotherapeutics Ltd
26 employees
CEO: Ron Babecoff biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and p...